Table 1.
Pathologic characteristics of clear cell carcinoma and their association with MMR status
| MMR-deficient cases (n = 10) | MMR-intact cases (n = 166) | P | ||
|---|---|---|---|---|
| Age(y) | 0.078 | |||
| <50 | 6 (60 %) | 54 (32.5 %) | ||
| ≥50 | 4 (40 %) | 112 (67.5 %) | ||
| Median | 46 | 53 | 0.041 | |
| Family history of cancer | 2 | 39 | 1.0 | |
| HNPCC history | 2 | 20 | 0.362 | |
|
Precursor Not present Adenofibroma Endometriosis both |
4 (40 %) 1 (10 %) 4 (40 %) 1 (10 %) |
61 (36.7 %) 22 (13.3 %) 69 (41.6 %) 14 (8.4 %) |
0.987 | |
| Stromal Hyalinization | 0.671 | |||
| Focal or absent | 8 (80 %) | 139 (83.7 %) | ||
| Diffuse | 2 (20 %) | 27 (16.3 %) | ||
| Nuclear Atypia | 0.139 | |||
| High grade | 5 (50 %) | 43 (25.9 %) | ||
| Low-medium grade | 5 (50 %) | 123 (74.1 %) | ||
| Signet ring cells | 0.603 | |||
| Not present | 10 (100 %) | 147 (88.6 %) | ||
| Present | 0 (0 %) | 19 (11.4 %) | ||
| Peritumoral Lymphocytes | 0.127 | |||
| Not present | 7 (70 %) | 146 (88 %) | ||
| Present | 3 (30 %) | 20 (12 %) | ||
| Intratumoral Stromal Inflammation | 0.001 | |||
| Diffuse | 5 (50 %) | 11 (6.6 %) | ||
| Focal | 5 (50 %) | 155 (93.4 %) | ||
| Plasma Cell Component | 0.037 | |||
| ≤50 % | 6 (60 %) | 145 (87.3 %) | ||
| >50 % | 4 (40 %) | 21 (12.7 %) | ||
| Tumor infiltrating Lymphocytes (/10HPF) | 0.249 | |||
| < 40 | 8 (80 %) | 151 (91 %) | ||
| ≥ 40 | 2 (20 %) | 15 (9 %) | ||
| Mitosis (/10HPF) | 5.1 | 6.4 | 0.499 | |
| Necrosis | 0.300 | |||
| Not present | 3 (30 %) | 73 (44 %) | ||
| Present | 7 (70 %) | 93 (56 %) | ||
| ARID1A (135 cases) | 0.027 | |||
| Negative | 8 (80 %) | 54 (43.2 %) | ||
| Positive | 2 (20 %) | 71 (56.8 %) | ||
| Stage | 0.462 | |||
| I/II | 6 | 110 | ||
| III-IV | 4 | 56 | ||